Analysis of thiopurine S-methyltransferase genotypes in Japanese patients with inflammatory bowel disease

Internal Medicine

Volumn 47, Issue 19, 2008, Pages 1645-1648

  Ban, Hiromitsu ^a   Andoh, Akira ^a   Tanaka, Aiko ^a   Tsujikawa, Tomoyuki ^a   Sasaki, Masaya ^a   Saito, Yasuharu ^a   Fujiyama, Yoshihide ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Crohn's disease; Leucopenia; Thrombocytopenia; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; MESALAZINE; THIOPURINE METHYLTRANSFERASE;

ADOLESCENT; ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HUMAN; JAPANESE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; AZATHIOPRINE; BONE MARROW; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GENOTYPE; HUMANS; INFLAMMATORY BOWEL DISEASES; JAPAN; LEUKOPENIA; MALE; METHYLTRANSFERASES; MIDDLE AGED; MUTATION; YOUNG ADULT;

EID: 56349104017     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.1268     Document Type: Article

References (17)

1. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 85: 717-722, 1990.
2. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R. Prantera C Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev: CD000545, 2000.
3. Hibi T, Ogata H. Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol 41: 10-16, 2006.
4. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 13: 563-567, 2004.
5. Derijks LJ, Gilissen LP, Engels LG, et al. Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease. Ther Drug Monit 28: 45-50, 2006.
6. Haglund S, Taipalensuu J, Peterson C, Almer S. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease-relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol 65: 69-77, 2007.
7. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130: 1047-1053, 2006.
8. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70: 439-444, 1976.
9. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298: 82-86, 1989.
10. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126: 608-614, 1997.
11. Kubota T, Nishida A, Takeuchi K, et al. Frequency distribution of thiopurine S-methyltransferase activity in red blood cells of a healthy Japanese population. Ther Drug Monit 26: 319-321, 2004.
12. Kumagai K, Hiyama K, Ishioka S, et al. Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics 11: 275-278, 2001.
13. Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol 38: 740-746, 2003.
14. Kubota T, Chiba K. Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, *3B and *3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositus. Br J Clin Pharmacol 51: 475-477, 2001.
15. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118: 1025-1030, 2000.
16. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 18: 395-400, 2003.
17. Lichtenstein GR, Sbreu MT, Cohen R, Tremaine W. [American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease]. Rev Gastroenterol Mex 71: 351-401, 2006 (in Spanish).